Ginkgo Bioworks Holdings (DNA) Revenue (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Revenue came in at $19.5 million in Q1 2026, down 49.06% YoY from $38.2 million in Q1 2025, and down 41.69% on a QoQ basis from $33.4 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Revenue (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Revenue data on file, last reported at $19.5 million in Q1 2026.
- Quarterly Revenue fell 49.06% year-over-year to $19.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $141.3 million (down 37.84% YoY) and the FY2025 annual result came in at $170.2 million, down 25.06% from the prior year.
- Revenue fell to $19.5 million in Q1 2026, from $33.4 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $243.1 million in Q4 2023 to a low of $19.5 million in Q1 2026.
- A 5-year average of $79.1 million and a median of $56.2 million in 2024 frame the typical range for Revenue.
- Annual changes were most pronounced in 2022 — Revenue surged 281.9% — and 2024, when it sank 81.96%.
- Tracing DNA's Revenue over 5 years: stood at $98.3 million in 2022, then surged by 147.33% to $243.1 million in 2023, then slumped by 81.96% to $43.8 million in 2024, then slipped by 23.84% to $33.4 million in 2025, then sank by 41.69% to $19.5 million in 2026.
- The last three Revenue figures came in at $19.5 million (Q1 2026), $33.4 million (Q4 2025), and $38.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | 20.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.16 Mn |
| Mar 31, 2026 | 19.47 Mn |
| Dec 31, 2025 | 33.40 Mn |
| Sep 30, 2025 | 38.84 Mn |
| Jun 30, 2025 | 49.60 Mn |
| Mar 31, 2025 | 38.23 Mn |
| Dec 31, 2024 | 43.85 Mn |
| Sep 30, 2024 | 89.05 Mn |
| Jun 30, 2024 | 56.21 Mn |
| Mar 31, 2024 | 37.94 Mn |
| Dec 31, 2023 | 243.09 Mn |
| Sep 30, 2023 | 55.43 Mn |
| Jun 30, 2023 | 80.57 Mn |
| Mar 31, 2023 | 80.70 Mn |
| Dec 31, 2022 | 98.29 Mn |
| Sep 30, 2022 | 66.40 Mn |
| Jun 30, 2022 | 144.62 Mn |
| Mar 31, 2022 | 168.41 Mn |
| Dec 31, 2021 | 148.49 Mn |
| Sep 30, 2021 | 77.61 Mn |